# INT230 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/int230

> INT230, sponsored by INTENSITY THERAPEUTICS, INC. (INTS): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | INT230 |
| Codes | INT230 |
| Sponsor | INTENSITY THERAPEUTICS, INC. (INTS) https://sec-api.dev/companies/ints/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### Jul 2024: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2024-11-13, last confirmed 2026-11-05.
- SEC Form 10-Q (accession 0001567264-26-000066): "In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the "INVINCIBLE-3 Study") testing INT230-6 as a monotherapy compared to the standard of care ("SOC") drugs in second- and third-line treatment for certain soft tissue sarcoma subtypes." https://www.sec.gov/Archives/edgar/data/1567264/000156726426000066/intensity-20260930.htm
- SEC Form 10-Q (accession 0001567264-26-000059): "In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the "INVINCIBLE-3 Study") testing INT230-6 as a monotherapy compared to the standard of care ("SOC") drugs in second- and third-line treatment for certain soft tissue sarcoma subtypes." https://www.sec.gov/Archives/edgar/data/1567264/000156726426000059/intensity-20260630.htm
- SEC Form 10-Q (accession 0001567264-26-000046): "In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the "INVINCIBLE-3 Study") testing INT230-6 as a monotherapy compared to the SOC drugs in second-and third-line treatment for certain soft tissue sarcoma subtypes." https://www.sec.gov/Archives/edgar/data/1567264/000156726426000046/intensity-20260331.htm
- SEC Form 10-Q (accession 0001567264-25-000103): "In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the "INVINCIBLE-3 Study") testing INT230-6 as a monotherapy compared to the SOC drugs in second-and third-line treatment for certain soft tissue sarcoma subtypes." https://www.sec.gov/Archives/edgar/data/1567264/000156726425000103/intensity-20250930.htm
- SEC prospectus (424B) (accession 0001628280-25-047924): "In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study, or INVINCIBLE-3 Study, testing INT230-6 as a monotherapy compared to the SOC drugs in second-and third-line treatment for certain soft tissue sarcoma subtypes." https://www.sec.gov/Archives/edgar/data/1567264/000162828025047924/intensitytherapeutics-424b.htm
- SEC Form 10-Q (accession 0001567264-25-000077): "In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the "INVINCIBLE-3 Study") testing INT230-6 as a monotherapy compared to the SOC drugs in second-and third-line treatment for certain soft tissue sarcoma subtypes." https://www.sec.gov/Archives/edgar/data/1567264/000156726425000077/intensity-20250630.htm
- SEC Form 10-Q (accession 0001567264-25-000039): "In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the "INVINCIBLE-3 Study") testing INT230-6 as a monotherapy compared to the SOC drugs in second-and third-line treatment for certain soft tissue sarcoma subtypes." https://www.sec.gov/Archives/edgar/data/1567264/000156726425000039/intensity-20250331.htm
- SEC Form 10-K (accession 0001567264-25-000010): "In July 2024, we initiated and dosed our first patient in a Phase 3 open-label, randomized study (the "INVINCIBLE-3 Study") testing INT230-6 as a monotherapy compared to the SOC drugs in second-and third-line treatment for certain soft tissue sarcoma subtypes." https://www.sec.gov/Archives/edgar/data/1567264/000156726425000010/intensity-20241231.htm
- SEC Form 10-Q (accession 0001567264-24-000052): "In July 2024, we dosed the first patients in the U.S. in a Phase 3 open-label, randomized study, or the INVINCIBLE-3 Study, testing INT230-6 as monotherapy compared to the SOC drugs in second and third line treatment" https://www.sec.gov/Archives/edgar/data/1567264/000156726424000052/intensity-20240930.htm

### Oct 2024: trial start

- Status: completed. Date confidence: month.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001567264-24-000053): "•October 2024: first patient dosed in the INVINCIBLE-4 Study." https://www.sec.gov/Archives/edgar/data/1567264/000156726424000053/ints20241113ex99120240930p.htm
- SEC Form 10-Q (accession 0001567264-24-000052): "In October 2024, we dosed the first patient in the INVINCIBLE-4 Study." https://www.sec.gov/Archives/edgar/data/1567264/000156726424000052/intensity-20240930.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/int230.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "INT230 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/int230

```bibtex
@misc{secapidev_pdufa_int230_20261116,
  title        = {INT230 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/int230}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_int230_20261116","title":"INT230 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/int230","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
